Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Rev. méd. Chile ; 149(3): 330-338, mar. 2021. ilus, graf
Article in Spanish | LILACS | ID: biblio-1389451

ABSTRACT

Background: Previous studies have assessed the role of Type 1 diabetes (DM1) antibodies as predictors of the natural history of disease. Aim: To determine the frequency and combinations of positivity for DM1 antibodies in patients with DM1 and the relationship between antibody positivity and the age of the patient. To explore the relationship between history of insulin therapy or diabetic ketoacidosis (DKA) at the onset of the disease with antibody positivity in a subsample. Material and Methods: Data was gathered from every sample processed for DM1 antibodies in our laboratory between January 2015 and September 2019. Medical records from 84 patients who tested positive for at least one antibody were revised to study the relationship between insulin therapy or DKA at the onset of the disease with antibody positivity. Results: Forty percent of DM1 antibody tests were positive. Among positive tests, 1, 2, 3 or 4 DM1 antibodies were detected in 48%, 33%, 17% and 3% of cases, respectively. The likelihood of testing positive was inversely related with age for ICA, GAD, IA-2, ZnT8 and directlyproportionalforIAA (p= −0,012; −0,013; −0,014; −0,009; 0,005 respectively). An association between DKA at the onset of the disease and IA-2 positivity was observed (Odds ratio (OR) 5.38 95% confidence intervals (CI) 1.79 − 16.16, P < 0.01). No association was found between IAA positivity and history of insulin therapy (OR 2.25 95%CI 0.63 − 7.90, P = 0.2403). The results obtained from this study represent a novel local profile of DM1 antibody data, highlighting a relationship between antibody positivity and age.


Subject(s)
Humans , Diabetic Ketoacidosis/epidemiology , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/epidemiology , Autoantibodies , Chile/epidemiology , Insulin/therapeutic use
2.
Rev. méd. Chile ; 148(9)sept. 2020.
Article in Spanish | LILACS | ID: biblio-1389323

ABSTRACT

Background: Vitamin K antagonist medications (VKA) are essential for the prevention of thromboembolic events, but their effectiveness is influenced by multiple factors, such as the type of medication chosen. Aim: To evaluate the efficacy in anticoagulant control of the bioequivalent and non-bioequivalent drugs of acenocoumarol compared to the reference drug. To evaluate the efficacy of warfarin bioequivalents available in Chile. To contrast the overall anticoagulant control efficacy between acenocoumarol and warfarin. Material and Methods: The results of 69333 outpatient oral anticoagulation controls were analyzed. Patient were separated in groups according to the drug that they used. Subsequently, the proportions of controls outside the range for each of acenocoumarol and warfarin bioequivalent drugs were compared. Acenocoumarol non-bioequivalent drugs were also compared with the reference drug. Acenocoumarol was compared with warfarin. Results: Acenocoumarol bioequivalent drugs and the reference drug had a similar proportion of controls outside the range (Odds ratios (OR) 0.812; 0.969; 0.974 and 0.963). Non-bioequivalent drugs had a higher proportion than the reference drug (OR 1.561 and 2.037). Both warfarin brands have a similar proportion of controls outside of the range (OR 1.050). Acenocoumarol compared to warfarin had a significant higher proportion of controls outside the range (OR 1.191). Conclusions: The pharmacological presentation of vitamin K antagonists could influence anticoagulant control. Therefore, it is not prudent to switch these presentations frequently.


Subject(s)
Humans , Thromboembolism , Vitamin K , Anticoagulants , Thromboembolism/prevention & control , Vitamin K/antagonists & inhibitors , Chile , Administration, Oral , Acenocoumarol , Anticoagulants/therapeutic use
3.
Rev. chil. infectol ; 37(3): 252-256, jun. 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1126117

ABSTRACT

Resumen Introducción: Las enfermedades producidas por micobacterias son de gran importancia clínica y epidemiológica presentando el complejo Mycobacterium tuberculosis (MTBc) una morbi-mortalidad mayor que la producida por micobacterias no tuberculosas (MNTB). La identificación tradicional está basada en sus características fenotípicas mediante procesos laboriosos e incapaces en algunos casos de distinguir entre especies. Actualmente, la mayoría de las técnicas utilizadas se basan en métodos moleculares que tienen alta veracidad, pero son complejas y de alto costo. La espectrometría de masas con desorción/ionización láser asistida por una matriz asociada a tiempo de vuelo (MALDI-TOF MS) se basa en la comparación del espectro proteico producido con respecto al de una base de datos de referencia. Objetivo: Evaluar el rendimiento de MALDI-TOF MS en la identificación de micobacterias comparado con métodos moleculares: Material y Métodos: Se analizaron 28 aislados de nueve especies distintas mediante MALDI-TOF MS. Resultados: Se identificó correctamente 78,5% de las aislados (22/28), concordante en 100% (9/9) de MNTB de crecimiento rápido, 60% (9/15) en las MNTB de crecimiento lento y 100% (4/4) de MTBc. Todas las especies no identificadas (6/6) pertenecen al complejo M. avium/intracellulare. Conclusión: MALDI-TOD MS es una metodología rápida, fácil y de bajo costo, con adecuada veracidad respecto a los métodos moleculares.


Abstract Background: Mycobacterial diseases are very important both clinically and epidemiologically. Mycobacterium tuberculosis complex (MTBc) infections confer higher morbidity and mortality rate than non-tuberculous mycobacteria (NTM) infections. Traditional species identification techniques are based on phenotypic characteristics which take a long time by laborious processes and in occasions are no conclusive. Currently, most used techniques are based on molecular methods, which are accurate but are expensive and complex. Matrix Assisted Laser Desorption/Ionization Time-of-Flight mass spectrometry (MALDI-TOF MS) is a simple, cheap and fast identification method based on comparing protein spectra with a reference database. Aim: To assess the performance of MALDI-TOF MS in the identification of MTBc and NTM, compared with molecular methods. Methods: For that purpose, 28 isolates of 9 different species were analyzed through MALDI-TOF MS. Results: 78.5% (22/28) of isolates were correctly identified, 100% (9/9) of rapidly growers NTM, 60% (9/15) of slow growing NTM and 100% (4/4) of MTBc. Every unidentified isolate (6/6) corresponded to M. avium/intracellulare complex. Conclusion: MALDI-TOF MS is fast, simple and cheaper than molecular methods and also has adequate accuracy.


Subject(s)
Humans , Mycobacterium , Tuberculosis , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
4.
Educ. méd. contin ; (48): 14-9, ago. 1995. ilus, tab
Article in Spanish | LILACS | ID: lil-178312

ABSTRACT

La morbilidad y la mortalidad de los pacientes diabeticos es elevada por el gran numero de complicaciones. El objetivo de este trabajo fue valorar en 83 pacientes hospitalizados por problemas de pie diabetico en el año 1994 la morbilidad derivada de las complicaciones tardias de la diabetes, los factores de riesgo vascular asociados, el tratamiento aplicado y la mortalidad perioperatoria. La prevalencia de complicaciones crónicas de la diabetes fue muy elevada para la evolución conocida de la enfermedad (55.4 por ciento presentaban dos o mas complicaciones adicionales al motivo de ingreso). Es de destacar tambien la alta prevalencia de otros factores de riesgo vascular, sobre todo la hipertensión (57.8 por ciento). en el 62.9 por ciento se practicó amputación y en el 1.2 por ciento simpatectomia lumbar. La mortalidad perioperatoria fue de 1.2 por ciento. El 83 por ciento de los pacientes declararon haber recibido educación diabetologica. La estancia media hospitalaria fue de 27.8 +- 14.5 días.


Subject(s)
Humans , Male , Female , Amputation, Surgical , Diabetes Mellitus , Hypertension , Indicators of Morbidity and Mortality , Diabetic Foot/diagnosis , Diabetic Foot/therapy
SELECTION OF CITATIONS
SEARCH DETAIL